Hypertension Drugs Flashcards
(91 cards)
1
Q
Phentolamine: Pharmacokinetics
A
- Short half life of 19 mins (blocks alpha receptor)
2
Q
Phentolamine: Adverse Effects
A
- Acute and prolonged HYPOTENSIVE EPISODES
- ORTHOSTATIC HYPOTENSION
- TACHYCARDIA, and
- CARDIAC ARRHYTHMIAS;
- weakness, dizziness, flushing, NASAL STUFFINESS, nausea, vomiting, and DIARRHEA
3
Q
Phenoxybenzamine: MOA
A
non-competitive antagonist (blocks alpha receptor)
4
Q
Phenoxybenzamine: Adverse Effects
A
many adverse effects similar to phentolamine, plus MIOSIS and occasionally causes severe allergic reactions (e.g., ANGIOEDEMA)
5
Q
Prazosin: MOA (non emphasized)
A
competitive antagonist of postsynaptic alpha1-adrenergic receptors
6
Q
Prazosin: Effects (non emphasized)
A
vasodilationof veins and
arterioles leads to a decrease in total peripheral resistance and blood pressure
7
Q
Prazosin: Clinical Applications
A
• Hypertension
- a late choice in JNC8 due to ALLHAT data showing > LIKELIHOOD OF STROKE AND CHF with DOXAZOSIN in comparison to CHLORTHALIDONE
• For PTSD nightmares; Raynaud syndrome
8
Q
Prazosin: Toxicities
A
- palpitations, edema, ORTHOSTATIC HYPOTENSION, syncope
- dizziness,headache, drowsiness, depression, nervousness
- decreased energy, weakness
- nausea, diarrhea, constipation
- urinaryfrequency, “RETROGRADE” EJACULATION, priapism
- blurred vision, reddened sclera
- nasal congestion
9
Q
Similar to prazosin (but differ with respect to α1a, α1b and α1d subtype selectivity)… marketed for benign prostatic
hypertrophy and also used to help kidney stones pass
- potential one drug solution for old man in wheelchair with BPH and hypertension…
A
tamsulosin, terazosin, (doxazosin)
10
Q
Clonidine: MOA (non-emphasized)
A
alpha2- adrenergic
receptor agonist, crosses blood- brain barrier
11
Q
Clonidine: Effects
A
• IV administration produces a transient increase in blood pressure
• Then get reduced sympathetic outflow from the CNS
- produces a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure
- Produces pain relief
- Beneficial for ADHD to reduce hyperactivity, impulsiveness, and distractibility
12
Q
Clonidine: Clinical Applications (non-emphasized)
A
- oral Immediate release tablets or transdermal patch for management of hypertension
- extended release tablets for treatment of ADHD
- continuous epidural administration as adjunctive therapy with opioids for treatment of severe cancer pain
- off-label includes: opioid withdrawal, postherpetic neuralgia, smoking cessation, Tourette syndrome
13
Q
Clonidine: Pharmacokinetics (non-emphasized)
A
oral, transdermal patch and epidermal solution formulations
14
Q
Clonidine: Toxicities
A
- Drowsiness
- Xerostomia (dry mouth)
- REBOUND HYPERTENSION IF DOSE IS MISSED
15
Q
α-methyldopa: MOA
A
selective agonist for α2-adrenergic receptors
16
Q
α-methyldopa: Effects (non-emphasized)
A
used as sympatholytic for hypertension due to reduced sympathetic outflow
17
Q
α-methyldopa: Clinical Applications
A
• For management of moderate to severe hypertension
- Not recommended for initial therapy of primary hypertension
- Continues to have a role in otherwise difficult to treat hypertension
• Remains a drug of choice for gestational hypertension (aka pregnancy-induced hypertension)
- (labetalol and long- acting nifedipine also used for gestational hypertension)
18
Q
α-methyldopa: Pharmacokinetics
A
oral and IV forms
19
Q
α-methyldopa: Toxicities
A
There is a lot • angina pectoris aggravation • Bell’s palsy • Amenorrhea • Sore or “black” tongue,
- POSITIVE COOMBS TEST
- SLE-LIKE SYNDROME
20
Q
Propranolol: MOA
A
NONSELECTIVE beta-adrenergic blocker (class II antiarrhythmic); competitively blocks response to beta1- and beta2- adrenergic stimulation
21
Q
Propranolol: Effects
A
- beta1 blockade decreases heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand
- beta2 blockade effects include blunting of bronchodilation and vasodilation in skeletal muscle
22
Q
Propranolol: Clinical Applications (non-emphasized)
A
• hypertension • angina pectoris • pheochromocytoma • essential tremor supraventricular arrhythmias • ventricular tachycardias • prevention of myocardial infarction • migraine headache prophylaxis • off-label: akathisia, antipsychotic-induced; performance anxiety; thyroid storm / thyrotoxicosis; tremor, lithium-induced
23
Q
Propranolol: Pharmacokinetics
A
given orally
24
Q
Propranolol: Toxicities
A
- bronchospasm, dyspnea
- COLD EXTREMITIES (ESPECIALLY INFANTS) – The reason B-blockers are contraindicated if peripheral vascular disease
• bradycardia, AV conduction
disturbance, congestive heart failure, cardiogenic shock, hypotension, syncope
- disrupted sleep with nightmares, drowsiness/fatigue, agitation
- hyperglycemia or hypoglycemia; hyperkalemia; hyperlipidemia
- abdominal pain, diarrhea, constipation, etc.
- conjunctival hyperemia, decreased visual acuity, mydriasis
25
Atenolol: MOA
• competitive β1-selective adrenergic receptor antagonist
• little or no effect on
β2- receptors except at high doses
26
Atenolol: Effects
beta1 blockade decreases heart rate, myocardial contractility, blood pressure, and myocardial oxygen demand
27
Atenolol: Clinical Applications
* treatment of hypertension, alone or in combination with other agents
* management of angina pectoris
• secondary prevention
postmyocardial infarction
• off-label: atrial fibrillation (rate control); cardiac risk reduction during surgery; pediatric hypertension; acute ethanol withdrawal (in combination with a benzodiazepine); supraventricular arrhythmias; unstable angina; ventricular arrhythmias
28
Atenolol: Pharmacokinetics
* PO: rapid but incomplete absorption
| * not lipophilic, does not cross BBB
29
Atenolol: Toxicities (non-emphasized)
* bradycardia (persistent), cardiac failure, chest pain, cold extremities, complete atrioventricular block, edema, hypotension, Raynaud's phenomenon, second degree atrioventricular block
* confusion, fatigue, headache, insomnia, lethargy, nightmares
* constipation, diarrhea, nausea
* impotence
30
another widely used beta1-selective blocker, shorter half-life than atenolol but available in extended release form; more lipid soluble so more likely to produce adverse CNS effects (e.g., lethargy/confusion, nightmares)
metoprolol
31
notable for having highest beta1-selectivity
bisoprolol
32
Captopril: MOA
competitive inhibitor of
| angiotensin- converting enzyme (ACE)
33
Captopril: Effects
* prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor and mitogen for cardiovascular remodeling
* lowers levels of angiotensin II --> Increased plasma renin activity and decreased aldosterone secretion
* Lowers BP
34
Captopril: Clinical Applications (non-emphasized)
* hypertension, add thiazide or loop diuretic if additional lowering is needed at max recommended dose
* acute hypertension (urgency/emergency)
* heart failure with reduced ejection fraction
* LV dysfunction following MI
* diabetic nephropathy
* off-label: aldosteronism (diagnosis), delay the progression of nephropathy and reduce risks of cardiovascular events HT + DM
35
Captopril: Pharmacokinetics
* Rapidly absorbed, ~60% bioavailability
* Substrate of CYP2D6 (major)
* excreted primarily in urine, 40-50% as unchanged drug
* t1/2: ~1.7 hrs, longer in renal impairment
36
Captopril: Toxicities
• COUGH
* hypotension
* headache
* drowsiness
* dizziness, orthostatic dizziness
• ANGIOEDEMA, anaphyllactoid reactions
* loss of/altered taste (especially captopril among class)
* rare cholestatic jaundice
* rare agranulocytosis, neutropenia, anemia, pancytopenia, thrombocytopenia
* myalgia, weakness
* polyuria, renal failure, renal insufficiency
37
another early ACEI, a prodrug with active form (enalaprilat) available for IV
enalapril (enalaprilat)
38
now widely used ACE inhibitor, longer half life permitting 1X/day dosing
benazepril
39
now widely used ACE inhibitor, longer half life permitting 1X/day dosing
lisonopril
40
Losartan: MOA
competitive nonpeptide angiotensin II receptor antagonist
41
Losartan: Effects (non-emphasized)
• blocks the vasoconstrictor and aldosterone- secreting effects of angiotensin II
• induces a more complete
inhibition of the renin- angiotensin system than ACE inhibitors
• does not affect the response to bradykinin
42
Losartan: Clinical Applications (non-emphasized)
* Treatment of diabetic nephropathy
* HT,alone or in combination with other antihypertensives
* Hypertension with left ventricular hypertrophy to reduce risk of stroke
* CKD and HT regardless of race or diabetes status, to improve kidney outcomes
* Heart failure if intolerant of ACE inhibitors
* Off-label: Marfan syndrome
43
Losartan: Pharmacokinetics
t1/2 = 2 hours
44
Losartan: Toxicities (non-emphasized)
* Adverse effects more common in those with diabetic nephropathy
* Hypotension, first-dose hypotension, orthostatic hypotension
* Fatigue, dizziness, fever
* Hypoglycemia, hyperkalemia
* Diarrhea,gastritis, nausea, weight gain
* anemia
• weakness,back/knee
pain
• Cough (< ACEI) bronchitis, nasal congestion
45
t1/2 ~ 6 -10 hrs, noteworthy in that NOT A PRODRUG requiring activation, excreted primarily in feces as unchanged drug
valsartan
46
t1/2 5-9 hrs, noteworthy for its relatively IRREVERSIBLE BINDING4
candesartan
47
Aliskiren: MOA
Direct renin inhibitor,
| resulting in blockade of the conversion of angiotensinogen to angiotensin I
48
Aliskiren: Effects
* Decreases the formation of angiotensin II (Ang II), a potent blood pressure- elevating peptide (via direct vasoconstriction, aldosterone release, and sodium retention)
* ACE inhibitor and ARB therapy can potentially be offset by increases in plasma renin actvitity (PRA), which is blocked by direct renin inhibitors
49
Aliskiren: Clinical Applications
Treatment of hypertension, alone or in combination with other antihypertensive agents
50
Aliskiren: Pharmacokinetics
* oral route, poor absorption
* see maximum effects in 2 weeks
* t1/2 ~ 24 hrs
51
Aliskiren: Toxicities
* few...
* skin rash (1%),rarely other hypersensitivity reactions
* diarrhea (2%)
• >300% increase in creatine
phosphokinase (1%)
* increased blood urea nitrogen, increased serum creatinine
* hyperkalemia, especially if combined or predisposing factors such as renal dysfunction or diabetes mellitus
* cough (1%)
52
Which drug is new, expensive, no obvious benefits, some evidence of increased risk of adverse events?
Aliskiren
53
Are ACE inhibitors contraindicated in pregnancy?
YES
54
Nifedipine: MOA
• prototypical dihydropyridine calcium channel blocker
55
Nifedipine: Effects
* causes relaxation of coronary vascular smooth muscle --> coronary vasodilation
* FREQUENCY – INDEPENDENT ... NOT CARDIOACTIVE
56
Nifedipine: Clinical Applications
* management of chronic stable or vasospastic angina
* treatment of hypertension
* off-label: HYPERTENSIVE EMERGENCY IN PREGNANCY; PULMONARY HYPERTENSION
57
Nifedipine: Toxicities
Common:
• flushing
•peripheral edema
• headache
Also see:
• palpitations
• gingival hyperplasia
58
dihydropyridine CCB with use limited to CAD and HT, but very widely used in part due to long t1/2 of 30-50 hrs
amlodipine
59
Verapamil: MOA
non-dihydropyridine CCB
60
Verapamil:
* produces relaxation of coronary vascular smooth muscle and coronary vasodilation
* FREQUENCY – DEPENDENT (I.E., CARDIOACTIVE)
61
Verapamil: Clinical Applications
* IV: supraventricular tachyarrhythmia
* Oral, treatment of:
- primary hypertension
- angina pectoris
- supraventricular tachyarrhythmia
• off-label: episodic migraine prevention (adults); hypertrophic cardiomyopathy
62
Verapamil: Toxicities
Common:
• headache
• gingival hyperplasia
• constipation
```
Also see:
• peripheral edema
• CHF/pulmonary edema
• hypotension, fatigue, dizziness, lethargy
• AV block, bradycardia
• flushing
• rash
• dyspepsia
• flu-like syndrome
```
63
Diltiazem: MOA
non- dihydropyridine calcium channel blocker
64
Diltiazem: Effects
* producing a relaxation of coronary vascular smooth muscle and coronary vasodilation
* FREQUENCY – DEPENDENT (I.E., CARDIOACTIVE)
65
Diltiazem: Clinical Applications
IV:
• control of rapid ventricular rate in patients with atrial fibrillation or atrial flutter
• conversion of paroxysmal supraventricular tachycardia (PSVT)
Oral:
• primary hypertension
• chronic stable angina or angina from coronary artery spasm
• off-label: anal fissures (topical); atrial fibrillation (rate control) (oral); stable narrow-complex tachycardia uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent (injection); hypertrophic cardiomyopathy; Raynaud phenomenon; hypertension (children)
66
Diltiazem: Toxicities
Common:
• edema
• headache
Also seen:
• Atrioventricular block, bradycardia, hypotension, extrasystoles, flushing, palpitations
• dizziness, pain, nervousness
• skin rash
• gout
• dyspepsia, constipation, vomiting, diarrhea
• injection site reaction
• weakness, myalgia
• rhinitis, pharyngitis, dyspnea bronchitis, cough
67
Direct Vasodilator:
Hydralazine: MOA
• Direct vasodilation of arterioles (with little effect on veins)
68
Direct Vasodilator:
Hydralazine: Effects
• Decreases systemic
| resistance
69
Direct Vasodilator:
Hydralazine: Clinical Applications
* Heart failure with reduced ejection fraction
| * HYPERTENSIVE EMERGENCY IN PREGNANCY
70
Direct Vasodilator:
Hydralazine: Pharmacokinetics
• oral or IV administration
71
Direct Vasodilator:
Hydralazine: Toxicities
* Cardiovascular: Angina pectoris, flushing, orthostatic hypotension, palpitations, paradoxical hypertension, peripheral edema, tachycardia, vascular collapse
* Central nervous system: Anxiety, chills, depression, disorientation, dizziness, fever, headache, increased intracranial pressure, psychotic reaction
* Dermatologic: Pruritus, rash, urticaria
* Gastrointestinal: Anorexia, constipation, diarrhea, nausea, paralytic ileus, vomiting
* Genitourinary: Dysuria, impotence
* Hematologic: Agranulocytosis, eosinophilia, erythrocyte count reduced, hemoglobin decreased, hemolytic anemia, leukopenia
* Neuromuscular and skeletal: Muscle cramps, peripheral neuritis, rheumatoid arthritis, tremor, weakness
* Ocular: Conjunctivitis, lacrimation
* Respiratory: Dyspnea, nasal congestion
* Miscellaneous: Diaphoresis, DRUG-INDUCED LUPUS-LIKE SYNDROME
72
Direct Vasodilator:
Nitroprusside: MOA
causes peripheral vasodilation by direct action on VENOUS and ARTERIOLAR smooth muscle
73
Direct Vasodilator:
Nitroprusside: Effects
• reduces peripheral resistance
• will increase cardiac
output by decreasing afterload
74
Direct Vasodilator:
Nitroprusside: Clinical Applications
• management of hypertensive crises
• acute
decompensated heart failure (HF)
• controlled hypotension to
reduce bleeding during surgery
• off-label... hypertension
during acute ischemic stroke
75
Direct Vasodilator:
Nitroprusside: Pharmacokinetics
* Administered IV
| * t1/2 = 2 mins
76
Direct Vasodilator:
Nitroprusside: Toxicities
• Cardiovascular: flushing, hypotension (excessive), palpitations, substernal distress, tachycardia
• Central nervous system:
apprehension, dizziness, headache, intracranial pressure increased, restlessness
* Dermatologic: rash
* Endocrine and metabolic: metabolic acidosis due to cyanide toxicity, hypothyroidism
* Gastrointestinal: abdominal pain, ileus, nausea, retching, vomiting
* Hematologic: methemoglobinemia, platelet aggregation decreased
* Neuromuscular and skeletal, ocular: muscle twitching and miosis due to thiocyanate toxicity
* Otic: tinnitus due to thiocyanate toxicity
* Respiratory: hyperoxemia due to cyanide toxicity
77
Direct Vasodilator:
Minoxidil: MOA
* produces vasodilation by directly relaxing arteriolar smooth muscle, with little effect on veins
* stimulationof hair growth
78
Direct Vasodilator:
Minoxidil: Effects
lowers arteriolar
| vascular resistance
79
Direct Vasodilator:
Minoxidil: Clinical Applications
• treatment of hypertension that is symptomatic or associated with target organ damage, and is not manageable with maximum therapeutic doses of a diuretic plus 2 other antihypertensives
• Use in milder degrees of
hypertension is not recommended because the benefit-risk ratio in such patients has not been defined.
80
Direct Vasodilator:
Minoxidil: Pharmacokinetics
t1/2 = ~4hrs
81
Direct Vasodilator:
Minoxidil: Toxicities
* Cardiovascular: ECG changes (T- wave changes 60%), edema (reversible, 7% to 10%), PERICARDIAL EFFUSION (OCCASIONALLY WITH TAMPONADE, 3%), angina pectoris, cardiac failure, pericarditis, tachycardia
* Dermatologic: hypertrichosis (80%)
* Endocrine and metabolic: sodium retention, water retention, weight gain
* Gastrointestinal: Nausea, vomiting
• Hematologic and oncologic:
transient decreased in hematocrit due to hemodilution
* Hepatic: ascites, increased serum alkaline phosphatase
* Respiratory: pulmonary edema
82
IV Antihypertensive Drugs For Hypertensive Emergencies
CCB — dihydropyridines:
Nicardipine: Contraindication
Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly
83
IV Antihypertensive Drugs For Hypertensive Emergencies
CCB — dihydropyridines:
Clevidipine: Contraindication
Contraindicated in patients with soybean, soy product, egg, and egg product allergy and in patients with defective lipid metabolism (eg, pathological hyperlipidemia, lipoid nephrosis or acute pancreatitis)
84
IV Antihypertensive Drugs For Hypertensive Emergencies
Vasodilators — Nitric-oxide dependent:
Sodium nitroprusside: Caution
Intra-arterial BP monitoring recommended to prevent "overshoot." Lower dosing adjustment required for elderly. Cyanide toxicity with prolonged use can result in irreversible neurological changes and cardiac arrest; thiosulfate is antidote
85
IV Antihypertensive Drugs For Hypertensive Emergencies
Vasodilators — Nitric-oxide dependent:
Nitroglycerin: Cautions
Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in volume-depleted patients
86
IV Antihypertensive Drugs For Hypertensive Emergencies
Vasodilators — direct:
Hydralazine: Cautions
BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients
87
IV Antihypertensive Drugs For Hypertensive Emergencies
Adrenergic blockers, beta1 selective:
Esmolol: Contraindication
Contraindicated in patients with concurrent beta-blocker therapy, bradycardia, or decompensated HF. Monitor for bradycardia. May worsen HF. Higher doses may block beta-2 receptors and impact lung function in reactive airway disease
88
IV Antihypertensive Drugs For Hypertensive Emergencies
Adrenergic blockers, combined alpha-1 selective and non selective beta :
Labetalol: Contraindication
Contraindicated in reactive airways disease or chronic obstructive pulmonary disease. Especially useful in hyperadrenergic syndromes. May worsen HF and should not be given in patients with secon- or third-degress heart block or bradycardia
89
IV Antihypertensive Drugs For Hypertensive Emergencies
Adrenergic blockers, nonselective alpha:
Phentolamine: Uses
Used in hypertensive emergencies induced by catecholamine excess (pheochromocytoma, interactions between monamine oxidase inhibitors and other drugs or food, cocaine toxicity, amphetamine overdose, or clonidine withdrawal)
90
IV Antihypertensive Drugs For Hypertensive Emergencies
Dopamine1-receptor agonist:
Fenoldopam: Contraindication
Contraindicated in patients at risk of increased intraocular pressure (glaucoma) or intracranial pressure and those with sulfite allergy
91
IV Antihypertensive Drugs For Hypertensive Emergencies
ACE inhibitor:
Enalaprilat: Contraindication
Contraindicated in pregnancy and should not be used in acute MI or bilateral renal artery stenosis. Mainly useful in hypertensive emergencies associated with high plasma renin activity. Dose not easily
adjusted. Relatively slow onset of action (15 min) and unpredictability of BP response
